[
  {
    "ts": null,
    "headline": "Pfizer Canada and BioNTech Receive Health Canada Approval of LP.8.1 Variant Adapted COVID-19 Vaccine",
    "summary": "Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX) \"BioNTech\" announced today that Health Canada has authorized the LP.8.1 variant adapted COMIRNATY® COVID-19 vaccine for individuals aged 6 months and older. The updated COMIRNATY® vaccine targets the Omicron LP.8.1 variant, one of the most recently circulating SARS-CoV-2 lineages.",
    "url": "https://finnhub.io/api/news?id=455ad90336aa24b570fa5874a617716f49404aadd3b4b3b3c3a74f384fce9fd6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755550800,
      "headline": "Pfizer Canada and BioNTech Receive Health Canada Approval of LP.8.1 Variant Adapted COVID-19 Vaccine",
      "id": 136417047,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX) \"BioNTech\" announced today that Health Canada has authorized the LP.8.1 variant adapted COMIRNATY® COVID-19 vaccine for individuals aged 6 months and older. The updated COMIRNATY® vaccine targets the Omicron LP.8.1 variant, one of the most recently circulating SARS-CoV-2 lineages.",
      "url": "https://finnhub.io/api/news?id=455ad90336aa24b570fa5874a617716f49404aadd3b4b3b3c3a74f384fce9fd6"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Canada, BioNTech Get Canadian Approval for Updated Covid-19 Vaccine",
    "summary": "Pfizer Canada, BioNTech Get Canadian Approval for Updated Covid-19 Vaccine",
    "url": "https://finnhub.io/api/news?id=d13750dc14dcc55504e5912e2beae5eb0e423d66db93012afdf15dec56c5709d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755538380,
      "headline": "Pfizer Canada, BioNTech Get Canadian Approval for Updated Covid-19 Vaccine",
      "id": 136421184,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Canada, BioNTech Get Canadian Approval for Updated Covid-19 Vaccine",
      "url": "https://finnhub.io/api/news?id=d13750dc14dcc55504e5912e2beae5eb0e423d66db93012afdf15dec56c5709d"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer’s sickle cell disease candidate fails Phase III trial",
    "summary": "This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.",
    "url": "https://finnhub.io/api/news?id=28785fc38fa0d26443a3e2d65befbd64c78315528cefd3d208c5cb7110af4bb4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755516345,
      "headline": "Pfizer’s sickle cell disease candidate fails Phase III trial",
      "id": 136408647,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.",
      "url": "https://finnhub.io/api/news?id=28785fc38fa0d26443a3e2d65befbd64c78315528cefd3d208c5cb7110af4bb4"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: Wedbush Adds CRWD, RBLX, GEV, NBIS To IVES AI 30 List",
    "summary": "Wedbush added CrowdStrike, Roblox, GE Vernova and Nebius to its IVES AI 30 list.",
    "url": "https://finnhub.io/api/news?id=b7c488352d95b21ae561caaf1adda8cd50aa73790382f3a953a87494c9107d0d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755514667,
      "headline": "Wall Street Lunch: Wedbush Adds CRWD, RBLX, GEV, NBIS To IVES AI 30 List",
      "id": 136407356,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1255728449/image_1255728449.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Wedbush added CrowdStrike, Roblox, GE Vernova and Nebius to its IVES AI 30 list.",
      "url": "https://finnhub.io/api/news?id=b7c488352d95b21ae561caaf1adda8cd50aa73790382f3a953a87494c9107d0d"
    }
  },
  {
    "ts": null,
    "headline": "These 3 Dividend Stocks Have Yields Above 5%, Plus They Raise Their Payouts Every Year",
    "summary": "These three businesses have been raising their payouts for at least 16 consecutive years.",
    "url": "https://finnhub.io/api/news?id=ee0d69f2fb0a37f376f98f52ebde4380db21b4bbf19871476475e10dbf90de5b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755508980,
      "headline": "These 3 Dividend Stocks Have Yields Above 5%, Plus They Raise Their Payouts Every Year",
      "id": 136408548,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "These three businesses have been raising their payouts for at least 16 consecutive years.",
      "url": "https://finnhub.io/api/news?id=ee0d69f2fb0a37f376f98f52ebde4380db21b4bbf19871476475e10dbf90de5b"
    }
  },
  {
    "ts": null,
    "headline": "Arvinas, Pfizer’s Vepdegestrant NDA Accepted by FDA for Breast Cancer Treatment",
    "summary": "Arvinas Inc. (NASDAQ:ARVN) is one of the best small cap stocks with biggest upside potential. On August 8, Arvinas, in collaboration with Pfizer Inc. (NYSE:PFE), announced that the US FDA accepted its New Drug Application/NDA for vepdegestrant. The drug is intended to treat patients with estrogen receptor-positive/ER+, human epidermal growth factor receptor 2-negative/HER2-, ESR1-mutated advanced […]",
    "url": "https://finnhub.io/api/news?id=aa2dc6139f88b4883e2b70b5b376cd2a93f88a80fab08d217abac028ca3b44f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755488467,
      "headline": "Arvinas, Pfizer’s Vepdegestrant NDA Accepted by FDA for Breast Cancer Treatment",
      "id": 136408649,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Arvinas Inc. (NASDAQ:ARVN) is one of the best small cap stocks with biggest upside potential. On August 8, Arvinas, in collaboration with Pfizer Inc. (NYSE:PFE), announced that the US FDA accepted its New Drug Application/NDA for vepdegestrant. The drug is intended to treat patients with estrogen receptor-positive/ER+, human epidermal growth factor receptor 2-negative/HER2-, ESR1-mutated advanced […]",
      "url": "https://finnhub.io/api/news?id=aa2dc6139f88b4883e2b70b5b376cd2a93f88a80fab08d217abac028ca3b44f2"
    }
  }
]